Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026)
Puma Biotechnology (PBYI) reported Income from Continuing Operations of 3753000.0 for Q1 2026, down 226.19% on a YoY basis from 2974000.0 in Q1 2025, and down 122.5% quarter-over-quarter from 16683000.0 in Q4 2025.
Puma Biotechnology (PBYI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Puma Biotechnology has reported Income from Continuing Operations for 17 years, with the latest figure at 3753000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 226.19% year-over-year to 3753000.0; the trailing twelve-month figure through Mar 2026 stood at 27629000.0 (up 290.96% YoY), and the FY2025 full-year result was 34356000.0, up 4858.45% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3753000.0, down from 16683000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 20317000.0 in Q3 2024, with the low at 11695000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 1699529.41 across 5 years, with a median of 1401000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations surged 1710.0% — and 2024, when it slumped 443.68%.
- Puma Biotechnology's Income from Continuing Operations stood at 5514000.0 in 2022, then tumbled by 88.72% to 10406000.0 in 2023, then dropped by 12.39% to 11695000.0 in 2024, then surged by 242.65% to 16683000.0 in 2025, then tumbled by 122.5% to 3753000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3753000.0 (Q1 2026), 16683000.0 (Q4 2025), and 8844000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Puma Biotechnology | 384.39 Mn | 282.84 Mn | 34.39 Mn | -3.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.75 Mn |
| Dec 31, 2025 | 16.68 Mn |
| Sep 30, 2025 | 8.84 Mn |
| Jun 30, 2025 | 5.86 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | -11.70 Mn |
| Sep 30, 2024 | 20.32 Mn |
| Jun 30, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -10.41 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | -5.51 Mn |
| Sep 30, 2022 | -360,000.00 |
| Jun 30, 2022 | 9.37 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | -44.67 Mn |
| Jun 30, 2021 | -5.11 Mn |